SCLX
Scilex Holding·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 3
High Gross Profit Margin
Significant Net Income Decline
Low Cash Short-term Debt Ratio
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SCLX
Scilex Holding Company
A biopharmaceutical company that develops non-opioid pain tablets for the treatment of acute and chronic pain
960 San Antonio Road, Palo Alto, CA 94303
--
Scilex Holding Company was incorporated in Delaware in February 2019. The Company is an innovative revenue generating company focused on acquiring, developing and commercializing non-opioid drug management products for the treatment of acute and chronic pain. The company believes that the company's innovative non-opioid product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients' lives. The company is committed to advancing and improving patient outcomes by targeting indications with high unmet needs and large market opportunities for non-opioid therapies in patients with acute and chronic pain.
Company Financials
EPS
SCLX has released its 2025 Q2 earnings. EPS was reported at -7.42, versus the expected -0.91, missing expectations. The chart below visualizes how SCLX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SCLX has released its 2025 Q3 earnings report, with revenue of 10.56M, reflecting a YoY change of -26.85%, and net profit of -257.82M, showing a YoY change of -5775.57%. The Sankey diagram below clearly presents SCLX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
